While an estimated 36 million Americans suffer from migraine[2], only one of every three people speak to a doctor[3] about their headaches. Of those, only half obtain the proper diagnosis[4]. In recognition of Migraine Awareness Week, September 6-12, 2015, Depomed Inc (NASDAQ:DEPO) has teamed with the American Migraine Foundation (AMF) to highlight the importance of seeking and consulting with a headache specialist who can help properly diagnose and correctly treat migraine.

“Given the disabling nature of a migraine, it is important for people who experience frequent attacks not to endure the pain in silence but rather to speak with a specialist in order to receive the proper diagnosis and to understand their treatment options,” said Srinivas G. Rao, MD, PhD, Senior Vice President and Chief Medical Officer of Depomed. “Depomed is deeply committed both to raising awareness about migraine and to supporting research activities aimed at helping better understand this disease.”

For more than 90 percent of those affected, migraine interferes with the activities surrounding everyday life including the ability to maintain business and personal activities.[5] In order to raise awareness of the impact of migraine and to encourage treatment, Depomed and AMF have produced “Demystifying Migraine,” a patient-focused animated story that provides a glimpse into the life of a migraine sufferer created to help individuals with the medical condition to take back control of their lives. As part of its ongoing commitment to help migraine sufferers find a treatment that works for them, Depomed will donate $1 to the AMF with every video view and $2 for every Share on Facebook and Twitter, up to $15,000. (Original Source)

Shares of Depomed Inc opened today at $27.85 and are currently trading down at $27.65. DEPO has a 1-year high of $33.74 and a 1-year low of $13.55. The stock’s 50-day moving average is $30.25 and its 200-day moving average is $25.34.

On the ratings front, Depomed has been the subject of a number of recent research reports. In a report issued on August 28, Roth Capital analyst Scott Henry maintained a Buy rating on DEPO, with a price target of $33, which implies an upside of 18.5% from current levels. Separately, on July 30, RBC’s Randall Stanicky downgraded the stock to Hold and has a price target of $32.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Scott Henry and Randall Stanicky have a total average return of 29.2% and 11.5% respectively. Henry has a success rate of 63.6% and is ranked #14 out of 3752 analysts, while Stanicky has a success rate of 58.9% and is ranked #399.

DepoMed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.